Treme climbs a new mountain
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
World Lung 2021 preview – China challenges and tremelimumab rises
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Asco 2020 – Bavencio “cure” suggests another cancer target for immunotherapy
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
